| Code | CSB-RA023978MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Emunkitug, targeting TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B), also known as TNFR2 or CD120b. TNFRSF1B is a cell surface receptor that binds tumor necrosis factor-alpha (TNF-α) and plays a critical role in immune regulation, inflammation, and cell survival. Unlike TNFR1, which mediates pro-inflammatory and apoptotic signals, TNFR2 primarily promotes anti-inflammatory responses and regulatory T cell expansion. Dysregulation of TNFRSF1B signaling is implicated in various autoimmune diseases, inflammatory disorders, and certain cancers where it can support tumor immune evasion.
Emunkitug is an investigational therapeutic antibody designed to modulate TNFR2 activity, with potential applications in oncology and immunology research. This biosimilar provides researchers with a valuable tool for investigating TNFR2-mediated signaling pathways, studying immune cell function, and exploring therapeutic strategies targeting this receptor. It supports various research applications in immunology, oncology, and inflammation studies.
There are currently no reviews for this product.